Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus POKONZA.
ALA-CORT vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid